A.P. Pharma’s third quarter net loss increases to $4 More information here .2 million A.P. Pharma, Inc. , a specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2011 and highlighted its recent corporate progress.0 million private positioning of common stock and warrants. In July 2011, the business commenced an intensive QT study designed to support the brand new Drug Application resubmission for APF530. The study will examine the result of APF530 on the QT interval in healthy volunteers. THE BUSINESS expects to report outcomes from this research in the first one fourth of 2012.
AORN conference: Integra LifeSciences launches four new products Integra LifeSciences introduced four services today at the AORN conference in Denver, Colorado. ‘We recognize that moments matter in the operating space, and that the busiest surgeons anticipate us to greatly help them minimize uncertainty within their methods,’ said Dan Reuvers, Vice President of Marketing and Product Development for Integra Surgical.’ Integra Surgical’s direct sales business and distributor network will sell the four new medical instruments.